Patents by Inventor Michael Gregory Bell

Michael Gregory Bell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS
    Publication number: 20240343740
    Abstract: In an embodiment, the present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof, and methods of using this compound for treating type II diabetes mellitus.
    Type: Application
    Filed: May 19, 2022
    Publication date: October 17, 2024
    Inventors: Francisco Javier AGEJAS CHICHARRO, Renato Alejandro BAUER, Michael Gregory BELL, Qi CHEN, Graham Robert CUMMING, Todd FIELDS, Douglas Linn GERNERT, Joseph Daniel HO, Talbi Abelkader KAOUDI, Thierry Jean MASQUELIN, Jose Miguel MINGUEZ ORTEGA, Julian PRIEGO SOLER, Antonio RODRIGUEZ HERGUETA, Eric Michael WOERLY
  • AHR AGONISTS
    Publication number: 20240199608
    Abstract: The present disclosure relates to certain AHR agonist compounds, their method of making, and to pharmaceutical compositions comprising the compounds and to methods of using the compounds to treat immune-mediated diseases, such as psoriasis and atopic dermatitis.
    Type: Application
    Filed: November 3, 2023
    Publication date: June 20, 2024
    Inventors: Michael Gregory BELL, Joel Robert CALVIN, Cheryl Ann CARSON, Lacie Marie CHAUVIGNE-HINES, Christian Alexander CLARKE, Frank Charles DORSEY, Douglas Linn GERNERT, Steven James GREEN, William Thomas MCMILLEN, Antonio NAVARRO, John Robert RIZZO
  • Aldosterone synthase inhibitor
    Patent number: 8778984
    Abstract: The present invention provides aldosterone synthase inhibitors of the formula: intermediates, methods for their preparation, pharmaceutical preparations, and methods for their use.
    Type: Grant
    Filed: June 7, 2012
    Date of Patent: July 15, 2014
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Paul J. Hoogestraat, Thomas Edward Mabry, Quanrong Shen, Ana Maria Escribano
  • Aldosterone Synthase Inhibitor
    Publication number: 20120322841
    Abstract: The present invention provides aldosterone synthase inhibitors of the formula: intermediates, methods for their preparation, pharmaceutical preparations, and methods for their use.
    Type: Application
    Filed: June 7, 2012
    Publication date: December 20, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventors: Michael Gregory Bell, Paul J. Hoogestraat, Thomas Edward Mabry, Quanrong Shen, Ana Maria Escribano
  • Compounds and methods for modulating FXR
    Patent number: 8106077
    Abstract: Compounds of formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: January 31, 2012
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Robert Anthony Doti, Matthew Scott Dowling, Michael James Genin, Peter Ambrose Lander, Tianwei Ma, Nathan Bryan Mantlo, Jason Matthew Ochoada, Lindsay Scott Stelzer, Ryan Edward Stites, Alan M Warshawsky
  • Compounds and methods for modulating FX-receptors
    Patent number: 7863302
    Abstract: Compounds of formula and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
    Type: Grant
    Filed: February 2, 2007
    Date of Patent: January 4, 2011
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Michael James Genin, Peter Ambrose Lander, Lindsay Scott Stelzer, Robert Anthony Doti, Francisco Javier Agejas-Chicharro, Ana Belen Bueno Melendo, Peter Rudolph Manninen, Jason Matthew Ochoada, Quanrong Shen, Alan M. Warshawsky, Tianwei Ma, Ryan Edward Stites
  • FXR agonists
    Patent number: 7846960
    Abstract: Compounds of formula wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: December 7, 2010
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Robert Anthony Doti, Michael James Genin, Peter Ambrose Lander, Tianwei Ma, Peter Rudolph Manninen, Jason Matthew Ochoada, Fucheng Qu, Lindsay Scott Stelzer, Ryan Edward Stites, Alan M. Warshawsky
  • FXR AGONISTS
    Publication number: 20090270460
    Abstract: Compounds of formula wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
    Type: Application
    Filed: May 22, 2007
    Publication date: October 29, 2009
    Inventors: Michael Gregory Bell, Robert Anthony Doti, Michael James Genin, Peter Ambrose Lander, Tianwei Ma, Peter Rudolph Manninen, Jason Matthew Ochoada, Fucheng Qu, Lindsay Scott Stelzer, Ryan Edward Stites, Alan M. Warshawsky
  • TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS
    Publication number: 20090149445
    Abstract: The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula I, including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula I.
    Type: Application
    Filed: July 15, 2008
    Publication date: June 11, 2009
    Inventors: Michael Joseph Coghlan, Jonathan Edward Green, Timothy Alan Grese, Prabhakar Kondaji Jadhav, Donald Paul Matthews, Mitchell Irvin Steinberg, Kevin Robert Fales, Michael Gregory Bell
  • COMPOUNDS AND METHODS FOR MODULATING FXR
    Publication number: 20090093524
    Abstract: Compounds of formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
    Type: Application
    Filed: May 22, 2007
    Publication date: April 9, 2009
    Inventors: Michael Gregory Bell, Robert Anthony Doti, Matthew Scott Dowling, Michael James Genin, Peter Ambrose Lander, Tianwei Ma, Nathan Bryan Mantlo, Jason Matthew Ochoada, Lindsay Scott Stelzer, Ryan Edward Stites, Alan M. Warshawsky
  • Compounds and methods for treating dyslipidemia
    Patent number: 7470705
    Abstract: The present invention discloses compounds of formula (I) wherein A, n, q, K, W, X, Y; Z, R1, R2, R3, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and its sequelae.
    Type: Grant
    Filed: March 17, 2005
    Date of Patent: December 30, 2008
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Guoqing Cao, Ana Maria Escribano, Maria Carmen Fernandez, Peter Ambrose Lander, Nathan Bryan Mantlo, Eva Maria Martin de la Nava, Ana Isabel Mateo Herranz, Daniel Ray Mayhugh, Xiaodong Wang
  • Compounds and Methods for Modulating Fx-Receptors
    Publication number: 20080306125
    Abstract: Compounds of formula. wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
    Type: Application
    Filed: February 2, 2007
    Publication date: December 11, 2008
    Inventors: Michael Gregory Bell, Michael James Genin, Peter Ambrose Lander, Lindsay Scott Stelzer, Robert Anthony Doti, Francisco Javier Agejas-Chicharro, Ana Belen Bueno Melendo, Peter Rudolph Manninen, Jason Matthew Ochoada, Quanrong Shen, Alan M. Warshawsky, Tianwei Ma, Ryan Edward Stites
  • Tricyclic steroid hormone nuclear receptor modulators
    Patent number: 7411072
    Abstract: The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula I, including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula I.
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: August 12, 2008
    Assignee: Eli Lilly and Company
    Inventors: Michael Joseph Coghlan, Jonathan Edward Green, Timothy Alan Grese, Prabhakar Kondaji Jadhav, Donald Paul Matthews, Mitchell Irvin Steinberg, Kevin Robert Fales, Michael Gregory Bell
  • Fluorinated trienes and their use as rxr modulators
    Publication number: 20040248919
    Abstract: The present invention relates to a method of modulating retinoid X receptor activity in a mammal, novel compounds and pharmaceutical compositions for modulating retinoid X receptor activity in a mammal, and methods of making compounds that modulate retinoid X receptor activity in a mammal. The compounds are represented by Structural Formula 1: The compounds of Structural Formual 1 are efficacious insulin sensitizers and do not have the undesirable side effects of increasing triglycerides or suppressing the thyroid hormone axis.
    Type: Application
    Filed: April 15, 2004
    Publication date: December 9, 2004
    Inventors: Michael Gregory Bell, Timothy Alan Grese, Douglas Linn Gernett, Nathan P. Yumibe, Marcus F. Boehm, Pierre-Yves Michellys, Robert J. Ardecky, Christopher M Mapes, Jyun-Hung Chen, John S. Tyhonas, Lawrence G. Hamann
  • Selective iglur5 receptor antagonists
    Patent number: 6579886
    Abstract: The present invention provides compounds of formula (I): wherein W represents hydrogen, C1-C4 alkyl, —CH2CO2H, or CO2H; and X represents hydrogen, C1-C4 alkyl, —CH2CO2H, or CO2H; with the proviso that at least one of W or X must be other than hydrogen; or a prodrug or a pharmaceutically acceptable salt thereof; which are useful for treating migraine.
    Type: Grant
    Filed: September 3, 2002
    Date of Patent: June 17, 2003
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Michael Edward Le Tourneau, Michael John Martinelli, Mark Alan Winter
  • Selective iglur5 receptor antagonists
    Publication number: 20030055081
    Abstract: The present invention provides compounds of formula (I): wherein W represents hydrogen, C1-C4 alkyl, —CH2CO2H, or CO2H; and X represents hydrogen, C1-C4 alkyl, —CH2CO2H, or CO2H; with the proviso that at least one of W or X must be other than hydrogen; or a prodrug or a pharmaceutically acceptable salt thereof; which are useful for treating migraine.
    Type: Application
    Filed: September 3, 2002
    Publication date: March 20, 2003
    Inventors: Michael Gregory Bell, Michael Edward LeTourneau, Michael John Martinelli, Mark Alan Winter
  • Selective &bgr;3 adrenergic agonists
    Patent number: 6265581
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective &bgr;3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: April 17, 2000
    Date of Patent: July 24, 2001
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Christine Ann Droste, Cynthia Darshini Jesudason, Donald Paul Matthews, John Hampton McDonald, III, David Andrew Neel, Christopher John Rito, Anthony John Shuker, Mark Alan Winter
  • Benzo[B]indeno[2, 1-D]thiophene compounds, intermediates, compositions, and methods
    Patent number: 6133458
    Abstract: The invention provides benzo[b]indenothiophene compounds, intermediates, formulations, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, cardiovascular-related pathological conditions including hyperlipidemia and related cardiovascular pathologies, and estrogen-dependent cancer.
    Type: Grant
    Filed: September 30, 1998
    Date of Patent: October 17, 2000
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Brian Stephen Muehl, Mark Alan Winter
  • Selective .beta.-3 adrenergic agonists
    Patent number: 6093735
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: July 1, 1999
    Date of Patent: July 25, 2000
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Christine Ann Droste, Cynthia Darshini Jesudason, Donald Paul Matthews, John Hampton McDonald, III, David Andrew Neel, Christopher John Rito, Anthony John Shuker, Mark Alan Winter
  • Selective .beta..sub.3 adrenergic agonists
    Patent number: 6075040
    Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
    Type: Grant
    Filed: May 2, 1997
    Date of Patent: June 13, 2000
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Thomas Alan Crowell, Cynthia Darshini Jesudason, Donald Paul Matthews, John Hampton McDonald, III, David Andrew Neel, Christopher John Rito, Anthony John Shuker, Mark Alan Winter